Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HAE | Common Stock | Award | +18.2K | +8.91% | 223K | May 15, 2023 | Direct | F1, F2, F3 | ||
transaction | HAE | Common Stock | Tax liability | -$141K | -1.59K | -0.71% | $89.21 | 221K | May 16, 2023 | Direct | F3, F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HAE | Non-qualified Stock Option (Right to Buy) | Award | $0 | +41.2K | $0.00 | 41.2K | May 15, 2023 | Common Stock | 41.2K | $89.16 | Direct | F5 |
Id | Content |
---|---|
F1 | The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. |
F2 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
F3 | This number includes unvested RSUs previously reported. |
F4 | Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. |
F5 | Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. |